Militants launch shell on exhibition complex near Damascus - televisionWorld August 20, 15:27
Cardinal Parolin: Dialogue of Roman Catholic and Orthodox Churches to help them feel unitySociety & Culture August 20, 8:27
Polina Dibrova, mother of three, wins Mrs. Russia 2017 beauty pageantSociety & Culture August 20, 4:41
Russian emergencies ministry plane returns from firefighting mission in ArmeniaWorld August 20, 4:39
East Ukraine conflict claimed nearly 3,000 civilian lives — ICRCWorld August 20, 1:56
Renowned Russian filmmaker Andrei Konchalovsky turns 80Society & Culture August 20, 0:48
One of seven injured in Surgut stabbing spree in critical condition — authoritiesSociety & Culture August 19, 23:51
Netanyahu expects to meet with Putin in Sochi on August 23 — Israeli premier’s officeRussian Politics & Diplomacy August 19, 22:47
Surgut attacker is identified as a local resident - investigationSociety & Culture August 19, 14:09
DARMSTADT, Germany, Oct. 26, 2015 /PRNewswire/. Merck Millipore, the Life Science business of Merck, today introduced Parteck® SRP 80, a new functional excipient for oral sustained-release formulations. Parteck® SRP 80 is a polyvinyl alcohol (PVA) based excipient specifically designed for modified-release applications, for optimization of pharmacokinetics and pharmacodynamics as well as the bioavailability of actives. The new excipient is fully synthetic, ensuring batch-to-batch and performance consistency and facilitating quality by design (QbD) and validation processes.
Photo - http://photos.prnewswire.com/prnh/20151026/NE38037-a
Suitable for direct compression processes, Parteck® SRP 80 allows for fast, easy and efficient formulation development as well as production processes. Parteck® SRP 80 is compliant with European Pharmacopoeia (Ph. Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia Excipients (JPE) and will be part of Merck Millipore's Emprove® program to facilitate regulatory filing and registration processes.
"Pharmaceutical excipients play an essential role in the development of safe and effective medicines," said Andrew Bulpin, Executive Vice President of Process Solutions, Merck Millipore. "Parteck® SRP 80 represents a new choice for customers looking to formulate prolonged release oral dosage forms with reliable performance profiles as well as robust and cost efficient production processes, which can translate into improved patient safety and compliance."
Experts from Merck Millipore will be available at booth #1636 at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Conference in Orlando, Florida to discuss Parteck® SRP 80 and the entire Emprove® portfolio.
For more information about Parteck® SRP 80 and Parteck® functional excipients, please visit www.merckmillipore.com/partecksrp80 or www.merckmillipore.com/parteck.
About Merck Millipore
Merck Millipore is the Life Science subsidiary of Merck, Darmstadt, Germany. As part of the global Life Science business of Merck, Merck Millipore offers a broad range of innovative performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.
For more information, please visit www.merckmillipore.com.
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
For more information, please visit www.merckgroup.com.
CONTACT: Jill DeCoste, +1 978 715 4670, firstname.lastname@example.org